



## Trius to Host Analyst and Investor Day in New York

SAN DIEGO, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company will host an analyst and investor day on Thursday, December 1 at 10:00 a.m. Eastern at the Millennium Broadway Hotel. In addition to a tedizolid phosphate overview by Trius management, the program will feature guest presentations by anti-infectives experts, including:

- Dr. Ralph Corey from Duke Clinical Research Institute presenting "Antibacterials Landscape & Need for New Therapeutic Options"
- Dr. Jeff Kingsley from SEERG presenting "Tedizolid — Perspectives from Prior Clinical Trials"

Trius management will also review the different outcomes that are possible from the first of its two Phase 3 studies in ABSSSI.

A live webcast of the event will be available in the Investors Relations section of Trius' website at <http://investor.triusrx.com/eventdetail.cfm?eventid=106194> or on the Events & Presentations page at <http://investor.triusrx.com/events.cfm>. A replay will be archived for 30 days following the call.

### About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, tedizolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments (SPA) with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S. and the European Union. In addition to the company's tedizolid phosphate clinical program, Trius is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit [www.triusrx.com](http://www.triusrx.com).

CONTACT: Public Relations Contact:

Jason Spark at Canale Communications, Inc.

[jason@canalecomm.com](mailto:jason@canalecomm.com)

619-849-6005

Investor Relations Contact:

Stefan Loren at Westwicke Partners, LLC

[sloren@westwicke.com](mailto:sloren@westwicke.com)

443-213-0507